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Abstract
An open-label, 60-day trial was conducted in 75 newly diagnosed tuberculosis (TB) patients to assess the adjunctive effect of the oral
immunomodulator Dzherelo with standard anti-TB chemotherapy (ATT) consisting of izoniazid, rifampicin, pyrazinamide and streptomy-
cin (HRZS) administered as directly observed therapy (DOT). Group 1 (n = 28) with cavitary TB and group 2 (n = 17) with inﬁltrating
pulmonary TB received 50 drops of Dzherelo twice daily in addition to HRZS. Group 3 (n = 30), which served as a control, received
ATT only. Liver damage indicators, bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) decreased to normal
levels in groups 1 and 2, but increased signiﬁcantly in group 3. Kidney failure markers, urea and creatinine, normalized in Dzherelo
recipients, but were unchanged or worsened in the ATT-only group. The changes in serum lactate dehydrogenase, catalase, malondial-
dehyde and diene conjugates suggested that Dzherelo downregulates TB-associated inﬂammation. The anti-inﬂammatory property of
Dzherelo was further supported by a favourable haematology proﬁle, reduced erythrocyte sedimentation rate and faster defervescence.
Radiological recovery was signiﬁcant in both Dzherelo groups, but not in the control group (p = 0.0085, p = 0.025 and p = 0.23,
respectively). These ﬁndings correlated positively with sputum smear conversion and clinical ﬁndings (r = 0.94; p < 0.05). Mycobacterial
clearance at day 30 was observed in 77%, 72% and 40% of patients in groups 1, 2 and 3, respectively. After 2 months sputum conver-
sion rates in groups 1, 2 and 3 were 93%, 89% and 70%, respectively. Sixty-day treatment outcomes in groups 1, 2 and 3 as assessed by
improvement in clinical features and respiratory function attained respective p-values of 0.008, 0.25 and 0.72, and 0.013, 0.48 and
0.0015. Dzherelo is thus useful as an immunotherapeutic adjunct in the management of TB.
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Introduction
Tuberculosis (TB) is a re-emerging global public health prob-
lem, the incidence of which has increased in the Ukraine, as
it has in other countries [1]. The incidence of TB in the
Odessa region was 178 cases per 100 000 individuals in
1962. It gradually declined to 73.0, 42.0 and 41.6 cases per
100 000 in 1972, 1982 and 1992, respectively. This trend,
however, then reversed, and by 2002 the incidence and
prevalence of TB had risen to 80.4 and 330 cases per
100 000, respectively. Mortality caused by TB more than
doubled from 10.2 per 100 000 to 21.6 per 100 000
between 1990 and 2001 [2]. The success rates of therapy in
Eastern Europe, including the Ukraine, as in Africa, are sub-
stantially below those in other regions of the world [1]. In
addition, the Ukraine has worsening epidemics of drug-resis-
tant TB, which is increasingly converging with HIV. Despite
the availability of anti-TB drugs the situation is far from ideal
and better therapeutic interventions are clearly needed to
reverse the current trend.
The oral immunomodulator Dzherelo, which contains
extracts of many plants (see below), is used in the Ukraine
for the management of both TB and HIV infections, including
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simultaneous infections by both. Dzherelo was approved in
1997 by the Ukrainian Ministry of Health as an immunomod-
ulating supplement and has been used extensively for various
indications, including chronic bacterial and viral infections,
autoimmune diseases and malignancy. In 1999 Dzherelo was
recommended by the Ukrainian health authorities as an
immune adjunct in the treatment of tuberculosis [3]. Previ-
ous clinical studies have indicated that Dzherelo can increase
CD4 T-lymphocytes and decrease viral load, and that it
improves the clinical response when combined with standard
anti-retroviral (ART) or anti-tuberculosis therapy (ATT).
Dzherelo has been found to reduce the incidence of oppor-
tunistic infections and reverse TB-associated wasting. Dzhe-
relo has also been found to alleviate the hepatotoxicity
associated with ATT, as evidenced by improvement in liver
function tests [4–10]. However, these studies have not dealt
with the effect of Dzherelo on other clinical parameters
associated with TB. Our study was thus aimed at deﬁning
the adjunct effect of Dzherelo on clinical and radiological
symptoms as well as on select biochemical and blood param-
eters among patients with cavitary and inﬁltrating pulmonary
TB. The addition of Dzherelo to standard ATT was com-
pared with a treatment regimen consisting of ATT alone.
Materials and Methods
Patients and ethical approval
The study involved 75 patients with newly diagnosed pulmo-
nary TB. All patients were males aged between 19 and
68 years. All patients who presented with newly diagnosed
pulmonary TB were enrolled in this study. No restrictive
exclusion criteria for study enrolment were set up except
that we disallowed patients who tolerated chemotherapy
poorly or had resistant strains of Mycobacterium tuberculosis.
Patients were divided into three groups. Group 1 contained
28 individuals with cavitary or destructive forms of pulmo-
nary TB; their mean ± standard deviation (SD) age was
46.5 ± 11.9 years (median 48 years). Group 2 contained 17
TB patients with the disseminated form of pulmonary TB
but without cavitary lesions; their mean age was
46.4 ± 13.7 years (median 47 years). The third group, which
received standard TB therapy without Dzherelo and served
as a comparison population, contained 30 patients with a
mean age of 42.7 ± 11.3 years (median 44 years) and
included patients with the cavitary and the inﬁltrating forms
of pulmonary TB. Patients were allocated to the Dzherelo
and ATT-only groups without formal randomization. All
study patients presented with the active form of pulmonary
TB. The most common symptoms were prolonged heavy
cough, pain in the chest, high fever, profuse night sweats,
fatigue, dyspnoea, haemoptysis, and loss of weight and appe-
tite. Active pulmonary tuberculosis was deﬁned by a medical
history and clinical ﬁndings compatible with tuberculosis, a
chest X-ray showing lung involvement, and a positive sputum
smear for acid-fast bacilli (AFB) and positive culture for
M. tuberculosis. Participation in this study was voluntary and
conduct of the trial was approved by the Internal Review
Board of the TB dispensary.
Treatment regimen
All patients received standard ATT, consisting of orally admin-
istered izoniazid (H; 300 mg), rifampicin (R; 600 mg) and
pyrazinamide (Z; 2000 mg), and intramuscular injection of
streptomycin (S; 1000 mg). The anti-TB drugs were procured
through the Ukraine’s centralized national supply system.
Patients in groups 1 and 2 also received 50 drops of Dzherelo,
given in a glass of water twice daily, usually 2 h after breakfast
and 30 min before supper. The treatment was administered
for 60 days as directly observed therapy (DOT) to patients
hospitalized in our TB dispensary at Kharkov National Medical
University, between March and May 2006.
The over-the-counter phytoconcentrate Dzherelo (Immu-
noxel) was generously supplied by Ekomed LLC (Kiev,
Ukraine). It contains a concentrated aqueous alcohol
extract from medicinal plants, including: aloe (Aloe arbores-
cens); common knotgrass (Polygonum aviculare); yarrow
(Achillea millefolium); centaury (Centaurium erythraea); snow-
ball tree berries (Viburnum opulus); nettle (Urtica dioica); dan-
delion (Taraxacum ofﬁcinale); sweet-sedge (Acorus calamus);
oregano (Origanum majorana); marigold (Calendula ofﬁcinalis);
sea buckthorn berries (Hippophae rhamnoides); elecampane
(Inula helenium); tormentil (Potentilla erecta); greater plantain
(Plantago major); wormwood (Artemisia sp.); Siberian golden
root (Rhodiola rosea); cudweed (Gnaphalium uliginosum); lico-
rice (Glycyrrhiza glabra); fennel (Foeniculum vulgare); chaga (In-
onotus obliquus); thyme (Thymus vulgaris); three-lobe
beggarticks (Bidens tripartita); sage (Salvia ofﬁcinalis); dog rose
(Rosa canina), and juniper berries (Juniperus communis).
Dzherelo was approved in 1997 by the Ukrainian Ministry
of Health as a dietary supplement. In 2006 it received the
status of a ‘functional food’, placing it in a superior category
of herbal supplements which can carry medical claims sub-
stantiated by clinical evidence.
Clinical endpoints
Primary endpoints of interest in this study were the effect of
prescribed therapy on clinical manifestations and radiological
and microbiological ﬁndings. The clinical manifestations of TB
that were evaluated comprised a complex of so-called ‘intoxi-
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cation’ symptoms and signs, including fever, night sweats, loss
of appetite, weight loss, weakness, depression, cough, and
lung crepitations, etc. [11,12]. The second aspect of clinical
evaluation concerned respiratory function and included
symptoms such as dyspnoea and lung function tests, including
total lung capacity (TLC), forced vital capacity (FVC), forced
expiratory volume (FEV), residual volume (RV), carbon mon-
oxide transfer factor, oxygen ubiquitin and calcium dioxide
according to the Dembo and Liberman classiﬁcation [11,12].
In both cases, the features or tests were given a score ranging
from 0 (severely affected) to 3 (absent or normal) and the
mean of these scores was used to deﬁne the overall result as
indicative of no, mild or severe abnormality. In addition, infor-
mation on the potential adverse effects of Dzherelo adminis-
tered in combination with chemotherapy was sought via
questionnaires completed by the patients.
Laboratory evaluation
A standard microbiological examination of a sputum smear
stained by the Ziehl–Neelsen method was conducted prior
to study entry and at days 30 and 60 from the start of treat-
ment. Isolates of M. tuberculosis were tested for sensitivity to
ﬁrst- and second-line anti-TB drugs with a commercially
available kit (Tulip Diagnostics Pvt Ltd, Goa, India) [7].
These tests were supplemented by regular examination of
haematological and biochemical parameters. Plasma levels
of catalase, malondialdehyde (MDA), lactate dehydrogenase
(LDH) and diene conjugates (DC) were measured as mark-
ers of oxidative stress, as described earlier [7].
Statistical analysis
The results were analysed with the statistical software Graph-
Pad (GraphPad Software, Inc., La Jolla, CA, USA). Baseline
quantitative values were compared with end-of-study values
by paired or unpaired Student’s t-test. Non-parametric or cat-
egorical values of treatment outcomes were compared by
McNemar or chi-square contingency tables. All statistical anal-
yses were performed on an intent-to-treat basis, involving the
total number of patients without subgrouping them into
responders and non-responders. The resulting probability
values were considered signiﬁcant at p £ 0.05.
Results
Lack of adverse reactions
During the entire follow-up no adverse reactions attributable
to Dzherelo were identiﬁed. In particular, no dyspepsia, mal-
aise, intolerance or allergic reactions were evident at any
time (data not shown).
Effect on body temperature
The dynamics of body temperature among treated patients
are shown in Fig. 1. All three groups showed a decline in
mean body temperature during the investigation. Group 1,
however, showed a clear tendency towards more rapid nor-
malization: the mean axillary temperature on day 30 reached
a ‘normal’ level, at 36.65 ± 1.24 C, compared with
37.17 ± 2.02 C in group 3 (p < 0.005). Group 2 had a simi-
lar rate of decline to group 1, whereas group 3 showed a
slower rate of decrease.
Effect on haematological parameters
The effects of ATT and Dzherelo on blood cell counts,
erythrocyte sedimentation rate (ESR) and haemoglobin are
shown in Table 1. Patients in groups 1 and 2 reacted in a
similar manner and displayed changes which appeared to be
speciﬁc to Dzherelo intervention as opposed to the effect of
ATT alone in group 3 patients. In particular, the relative con-
tent of lymphocytes almost tripled among Dzherelo-treated
patients, reaching normal levels, whereas patients in the con-
trol group failed to attain normal values. Elevated counts of
cells, such as neutrophils, eosinophils and total leukocytes,
commonly associated with inﬂammation, were reduced to a
greater extent in Dzherelo-treated patients, although the
decrease was also statistically signiﬁcant in group 3 patients.
By contrast, monocyte levels were almost unchanged among
patients who received Dzherelo, whereas patients in the
comparison group had a greater reduction in these cells.
Other cells such as erythrocytes behaved in a similar manner
in all three groups. Erythrocyte sedimentation rate declined
faster in the Dzherelo groups. Haemoglobin concentrations
decreased at the same rate in all patients. In general,
Dzherelo appeared to have greater effect in normalizing the
haematology proﬁle than ATT treatment alone.
Effect on liver and kidney function
Serum biochemistry markers of liver and kidney function
improved markedly among Dzherelo recipients, whereas
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FIG. 1. Mean axillary temperature (C) followed for 60 days.
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patients in group 3 showed a decline in liver function
(Table 2). All three evaluated hepatic markers, bilirubin, ala-
nine aminotransferase (ALT) and aspartate aminotransferase
(AST), decreased in groups 1 and 2 but increased in group 3
in a statistically signiﬁcant manner. Levels of urea and creati-
nine normalized in Dzherelo recipients but were unchanged
or worsened in ATT-alone patients.
Effect on oxidative stress markers
The effect of therapy on plasma levels of catalase, MDA,
LDH and DC as markers of oxidative stress and lipid peroxi-
dation are presented in Table 3. There is a clear impression
that Dzherelo helps to slow down the pathological processes
associated with TB and its treatment. For example, concen-
trations of LDH, a marker indicative of cell injury and inﬂam-
mation, in patients receiving Dzherelo remained within the
normal range (0.8–2.5 IU), but almost tripled in patients on
ATT alone. Increases in levels of DC and MDA were lower
in Dzherelo recipients than in ATT-alone recipients. The
decrease in antioxidant catalase levels was smaller in the
Dzherelo groups, whereas, among those on ATT alone,
these were more than halved.
Effect on mycobacterial clearance
Bacterial clearance, evaluated by repeated sputum Ziehl–
Neelsen staining at monthly intervals, is shown in Fig. 2. At
day 30, 77% and 72% of patients in groups 1 and 2, respec-
tively, had negative ﬁndings, whereas only 40% of patients in
group 3 showed sputum clearance of bacteria. After 60 days
the corresponding ﬁgures were 93%, 89% and 70%, respec-
TABLE 2. Changes in biochemical markers of liver and
kidney function
Patients
Bilirubin,
lM/L
ALT,
U/L
AST,
U/L
Urea,
lM/L
Creatinine,
lM/L
Group 1
at entry
29.22 ± 1.45 110 ± 9 76 ± 6 9.21 ± 0.22 76.50 ± 5.23
Day 60 11.23 ± 0.75
p < 0.0001
47 ± 8
p < 0.0001
39 ± 3
p < 0.0001
6.97 ± 0.23
p < 0.0001
68.57 ± 2.43
p < 0.0001
Group 2
at entry
32.06 ± 4.32 135 ± 24 134 ± 10 8.66 ± 0.53 83.32 ± 5.67
Day 60 18.19 ± 1.65
p < 0.0001
59 ± 11
p < 0.0001
67 ± 7
p < 0.0001
6.82 ± 0.26
p < 0.0001
76.22 ± 5.24
p < 0.0001
Group 3
at entry
22.54 ± 2.52 79 ± 11 79 ± 7 7.99 ± 0.54 83.40 ± 6.40
Day 60 26.22 ± 4.12
p < 0.0001
118 ± 21
p < 0.0001
68 ± 19
p = 0.0043
7.88 ± 0.32
p = 0.3411
89.36 ± 6.26
p = 0.0006
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
TABLE 1. Effect of treatment on peripheral blood in tuberculosis patients
Patients
Neutrophils
segmented, %
Neutrophils
banded, % Eosinophils, % Monocytes, % Lymphocytes, %
Leukocytes,
109/k
Erythrocytes,
1012/L
ESR,
mm/h
Haemoglobin,
g/L
Group 1 at
baseline
65.48 ± 1.12 12.8 ± 1.06 4.88 ± 0.37 9.12 ± 0.38 10.72 ± 0.55 12.17 ± 0.60 4.38 ± 0.07 31.57 ± 1.80 140.95 ± 2.23
Day 30 6.50 ± 0.43
p < 0.0001
2.00 ± 0.22
p < 0.0001
6.51 ± 0.51
p < 0.0001
30.40 ± 0.9
p < 0.0001
8.41 ± 0.18
p < 0.0001
4.46 ± 0.08
p = 0.0002
13.52 ± 0.6
p < 0.0001
136.90 ± 1.61
p < 0.0001
Day 60 54.03 ± 1.30
p < 0.0001
5.77 ± 0.39
p < 0.0001
1.23 ± 0.23
p < 0.0001
8.17 ± 0.56
p < 0.0001
29.73 ± 1.1
p < 0.0001
7.44 ± 0.29
p < 0.0001
4.15 ± 0.08
p < 0.0001
10.77 ± 0.9
p < 0.0001
119.00 ± 2.19
p < 0.0001
Group 2 at
baseline
59.5 ± 3.00 17.50 ± 2.81 5.10 ± 0.75 7.50 ± 0.72 8.52 ± 0.78 14.51 ± 1.96 4.28 ± 0.06 28.10 ± 1.1 139.83 ± 3.66
Day 30 8.17 ± 0.54
p < 0.0001
6.67 ± 2.40
p = 0.1815
31.00 ± 1.31
p < 0.0001
8.86 ± 0.26
p < 0.0001
4.68 ± 0.06
p < 0.0001
10.50 ± 1.31
p < 0.0001
149.67 ± 2.74
p < 0.0001
Day 60 57.00 ± 2.13
p = 0.0086
6.00 ± 0.58
p < 0.0001
6.83 ± 0.87
p = 0.0201
27.17 ± 1.83
p < 0.0001
7.62 ± 0.44
p < 0.0001
3.88 ± 0.06
p < 0.0001
10.17 ± 1.25
p < 0.0001
123.67 ± 2.99
p < 0.0001
Group 3 at
baseline
67.14 ± 0.89 14.25 ± 0.56 4.10 ± 0.50 8.54 ± 0.43 9.65 ± 0.65 12.86 ± 0.97 4.36 ± 0.09 32.91 ± 1.28 147.50 ± 2.52
Day 30 9.40 ± 0.39
p < 0.0001
7.93 ± 0.26
p < 0.0001
7.99 ± 0.26
p < 0.0001
16.55 ± 0.93
p < 0.0001
11.82 ± 0.68
p < 0.0001
4.37 ± 0.05
p = 0.5968
18.35 ± 1.23
p < 0.0001
140.50 ± 1.86
p < 0.0001
Day 60 67.50 ± 1.14
p = 0.178
7.10 ± 0.34
p < 0.0001
3.10 ± 0.38
p < 0.0001
3.10 ± 0.38
p < 0.0001
18.20 ± 1.11
p < 0.0001
10.29 ± 0.72
p < 0.0001
3.67 ± 0.06
p < 0.0001
14.15 ± 1.16
p < 0.0001
120.40 ± 1.88
p < 0.0001
p-values are intra-group statistical comparisons of baseline with day-30 or day-60 values.
ESR, erythrocyte sedimentation rate.
TABLE 3. Changes in oxidative stress markers
Patients
Lactate dehydrogenase, IU Catalase, Iu Diene conjugates, lM/L Malondialdehyde, nM/mL
Day 0 Day 60 Day 0 Day 60 Day 0 Day 60 Day 0 Day 60
Groups 1 and
2 (n = 45)
1.84 ± 0.2 2.5 ± 0.3
p < 0.0001
4.9 ± 0.36 3.8 ± 0.2
p < 0.0001
55.5 ± 5.0 58.5 ± 4.7
p < 0.0001
3.6 ± 0.4 3.99 ± 0.4
p < 0.0001
Group 3
(n = 30)
1.79 ± 0.41 4.38 ± 0.54
p < 0.0001
5.49 ± 0.26 2.65 ± 0.3
p < 0.0001
37.99 ± 2.9 102.3 ± 8.86
p < 0.0001
4.38 ± 0.26 4.72 ± 0.6
p = 0.0061
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tively. The difference between the two groups receiving
Dzherelo was not signiﬁcant at either test-point (p = 0.42,
p = 0.32, respectively, as tested by non-parametric chi-
square analysis). When groups 1 and 2 were compared with
group 3, the statistical difference was highly signiﬁcant at
30 days (p < 0.0000001, p < 0.000005, respectively) and
60 days (p = 0.000028, p = 0.00088, respectively).
Effect on clinical and respiratory symptoms
The response rates of patients receiving chemotherapy with
or without immunotherapy are shown in Figs 3 and 4.
Changes in two categories of clinical manifestations were
evaluated: the ﬁrst was a complex of so-called ‘intoxication’
symptoms and the second represented ‘respiratory func-
tion’. At study entry the degree of severity of both catego-
ries of clinical manifestations was similar in all three groups.
Contingency table analysis comparing baseline results
between groups 1 vs. 2, 1 vs. 3, and 2 vs. 3 reveals p-values
of 0.40, 0.28 and 0.002, respectively, for the intoxication
and 0.22, 0.21, and 0.0008, respectively, for the respiratory
function categories of clinical features. The inter-group dif-
ferences between Dzherelo recipients and ATT-alone recip-
ients became greater by the end of the ﬁrst month. After
60 days of treatment, the p-values for comparisons between
groups 1 vs. 2, 1 vs. 3 and 2 vs. 3 reached 0.13, 0.004 and
0.22, and 0.13, 0.00002 and 0.13, respectively, for the intox-
ication and respiratory function categories of clinical fea-
tures, respectively. The intra-group differences between
baseline and 30 days were not signiﬁcant by McNemar test.
The p-values for groups 1, 2 and 3 were 0.07, 0.61 and 0.7,
respectively, for intoxication, and 0.11, 1.0 and 0.5, respec-
tively, for respiratory function categories. However, intra-
group changes between baseline status and 60-day treat-
ment outcomes for groups 1, 2 and 3 for intoxication and
respiratory function attained p-values of 0.008, 0.25 and
0.72, respectively, and 0.013, 0.48 and 0.0015, respectively.
These ﬁndings indicate that the addition of Dzherelo to
ATT enhances the efﬁcacy of ATT and achieves statistically
signiﬁcant favourable clinical responses at 2 months after
treatment initiation.
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FIG. 2. Presence of acid-fast bacilli in sputum smears (percentage of
patients) at baseline and at 30 and 60 days.
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Effect on radiological manifestations
Results of chest X-ray evaluation of lung segments affected
by cavitary and non-cavitary inﬁltrating TB are presented in
Fig. 5. Chi-square contingency table analysis comparing
baseline differences between groups 1 vs. 2, 1 vs. 3 and 2
vs. 3 showed that p-values were 0.39, 0.82 and 0.18,
respectively, indicating that at study entry patients in differ-
ent treatment groups had similar levels of pulmonary inva-
sion. After 60 days the differences in response to
treatment became highly signiﬁcant for Dzherelo recipients,
but not for ATT-treated patients. Observed radiological
improvement as determined by the McNemar categorical
test for groups 1, 2 and 3 attained p-values of 0.0085,
0.025 and 0.23, respectively. Thus, the healing rate was
greater among patients on Dzherelo than among those who
received ATT only. These observations correlated positively
with microscopy and clinical ﬁndings (r = 0.94; p < 0.05).
Discussion
This open-label, comparative study in a group of newly diag-
nosed TB patients at our dispensary reveals that when stan-
dard, ﬁrst-line anti-TB drugs are combined with Dzherelo,
signiﬁcant clinical and radiological improvements and clear-
ance of M. tuberculosis take place at a higher rate than in
patients on ATT alone. Biochemical and haematological anal-
yses of blood samples supported this favourable adjunctive
effect of Dzherelo, which did not show any adverse effects
throughout the investigation. Our ﬁndings support earlier
clinical studies of Dzherelo demonstrating similar results
[3–10]. The proportion of TB patients cured according to
sputum culture and radiology was two- to four-fold higher
among Dzherelo recipients. Furthermore, the combination
therapy gave results after a much shorter period.
Earlier indications showed Dzherelo to exhibit anti-inﬂam-
matory properties [5–7]. This notion is reinforced by the
ﬁndings of this study. The decline in elevated body tempera-
ture to < 36.6 C occurred in the Dzherelo-treated groups
within 30 days, as opposed to the control group, where this
happened only after 60 days. As fever is an independent indi-
cator associated with an aggressive form of TB, the outcome
of treatment is likely to be inﬂuenced positively by Dzherelo
[13]. Similarly, the indices of inﬂammation such as leukocyto-
sis, neutrophilia and eosinophilia tended to return to normal
at an earlier date and more strikingly in Dzherelo recipients
than in patients on ATT alone. Elevated numbers of these
cells are known to be associated with active pulmonary TB
and their normalization is considered to indicate a favourable
effect on the course of disease [14,15]. The observed
changes in the blood proﬁle are paralleled by ﬁndings from
previous studies; in particular, lymphocyte counts almost tri-
pled among Dzherelo recipients, whereas in control patients
they failed to reach normal levels. Restoration of lymphocyte
counts is considered to have a favourable prognostic signiﬁ-
cance [15]. Although Dzherelo did not affect erythrocyte
counts, it did reduce the ESR (considered to be a marker of
TB-associated inﬂammation) much more efﬁciently than ATT
alone [16].
Lactate dehydrogenase, another indicator of inﬂammation,
had a three-fold slower rate of accumulation in the Dzhe-
relo group than in the ATT-alone group, suggesting a
favourable anti-inﬂammatory property of Dzherelo [17].
During pulmonary inﬂammation in patients with active TB
increased amounts of reactive oxygen species are produced
as a consequence of the phagocyte respiratory burst.
Among the manifestations of these free radical-mediated
processes are higher concentrations of DC and MDA
[18,19]. Increases in DC and MDA were lower in Dzherelo
recipients than in ATT-alone patients, suggesting that herbal
components in this preparation can downregulate the
inﬂammatory process. Observed changes in antioxidant cat-
alase levels in TB patients are in line with these ﬁndings as
the rate of decline of this enzyme was twice as slow in the
Dzherelo groups as in the ATT-alone group. The oxidative
injury is an essential component of inﬂammatory damage
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and it is clear that the reversal of excessive peroxidation
favourably inﬂuences the outcome of the disease by lessen-
ing the impact on pulmonary tissue damage and respiratory
distress [20].
The hepatotoxicity induced by anti-TB drugs has serious
adverse consequences for treated patients and imposes limi-
tations on treatment options [21]. The addition of Dzherelo
reversed ATT-associated liver damage, as evidenced by the
two- to three-fold reduction of baseline bilirubin and AST
and ALT levels in the Dzherelo groups compared with the
ATT-alone group, in which all three liver function parame-
ters continued to rise. These observations conﬁrm previous
clinical studies in which Dzherelo has been shown to counter
the hepatotoxicity of anti-TB as well as anti-HIV drugs [5–7].
Renal failure characteristics as assessed by urea and creati-
nine output seemed to improve upon intake of Dzherelo,
whereas in group 3 patients there was practically no
improvement.
The conversion of sputum smear from positive to negative
is considered a critical indicator of the efﬁcacy of anti-TB
intervention [22]. We observed that Dzherelo accelerated
and signiﬁcantly enhanced bacillary clearance (Fig. 2). A large,
prospective Canadian study evaluating 428 TB cases showed
that 48% of patients had converted after 4 weeks [22], a
reduction which seems to be in line with our 40% conver-
sion rate in the ATT-alone group, but is smaller than the
77% and 72% clearance rates in groups 1 and 2, respectively.
In a recently reported study from India, the 2-month sputum
conversion rate in newly diagnosed TB was 58%, which is
also lower than our Dzherelo-facilitated conversion rates at
60 days (i.e. 93% and 89%, respectively) [23]. The difference
between ATT-alone and ATT-plus-Dzherelo recipients was
highly signiﬁcant at both time-points, indicating that adminis-
tration of this botanical immunomodulator produces better
results than standard treatment. A longer follow-up study is
needed to assess the bacteriological relapse rate in our
patients.
The mycobacterial clearance results agree with our clinical
ﬁndings. Based on two categories of clinical evaluation, fea-
tures of intoxication and respiratory function, it became
apparent that the combination of Dzherelo with ATT pro-
duces a faster and more profound beneﬁcial effect than ATT
alone. As Figs 3 and 4 show, only 50.0% and 33.3%, respec-
tively, of patients on ATT alone became free of indicators
after 60 days of treatment. By contrast, in groups 1 and 2,
respectively, 85.7% and 94.1% were alleviated of intoxication
features, and 85.7% and 76.5% became free of respiratory
function problems. The proportion of patients with mild
problems also fell signiﬁcantly in Dzherelo-treated patients.
Although the classiﬁcation of clinical features into the two
categories used in this study is not employed in countries
outside the former Soviet Union, these categories continue
to be commonly used in the Ukraine and have been proven
reliable by several generations of Ukrainian TB physicians
since the 1950s [11,12,24]. These categories, especially when
used in combination with bacteriological and chest X-ray
evaluations, appear to facilitate the dependable assessment of
the efﬁcacy of anti-TB intervention.
Indeed, radiographic examination of lung segments affected
by cavitary and non-cavitary TB lesions unequivocally sup-
ported the beneﬁts of adding Dzherelo to the standard TB
treatment regimen. As Fig. 5 shows, there was clear
improvement in groups 1 and 2 after 60 days compared with
group 3, in which 30% of patients still had three or more
affected pulmonary segments. Our ﬁndings indicate that,
although radiographic involvement in one or two segments
persisted in all treated patients at 60 days, the length of fol-
low-up was perhaps too short to see complete pulmonary
recovery. For this reason a longer study is required.
Throughout the study we observed statistically signiﬁcant
discrepancies between groups 1 and 2 in terms of response
at certain therapy endpoints, for which we do not have valid
explanations. It is likely that these differences are attributable
to differences in pulmonary lesions in these groups. It has
been reported that a predominant Th1 immune response is
observed in non-cavitary patients, whereas cavitary-involved
segments exhibit the presence of Th2 lymphocyte subsets
[25]. This needs to be explored further in a larger popula-
tion of patients.
Several immunomodulators have been tested as adjuvants
for TB therapy. These include likopid, interferon-c (IFN-c)
and environmental Mycobacterium vaccae, all of which have
shown promising results in preliminary trials. Likopid is a
synthetic lipid analogue of bacterial cell wall which has
been developed in Russia [26]. The combination of likopid
with ATT in patients with pulmonary TB resulted in posi-
tive clinical effects, including bacterial culture conversion in
80% of cases, a lower rate of positive sputum staining, lack
of intoxication, and accelerated resolution of pulmonary
inﬁltrations. Such effects were not observed in control
patients who received conventional ATT. Interferon-c has
been used as an adjunct immunotherapy for TB since 1997
[27]. Several clinical trials of inhaled or injected IFN-c have
shown positive clinical outcomes, although to lesser extent
than in likopid-treated cases [27–29]. Environmental
M. vaccae has shown encouraging results in some trials, but
was ineffective in others [30–32]. For example, treatment
of drug-susceptible pulmonary TB with M. vaccae did not
improve radiological responses or resolve cavitary disease
[32].
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In conclusion, the phytopreparation Dzherelo, which has
been used as an immunomodulating adjuvant to standard TB
therapy, has been shown to be safe and capable of reversing
ATT-associated hepatotoxicity. In addition, Dzherelo seems
to reduce inﬂammation, as evidenced by several haematologi-
cal and biochemical markers, and signiﬁcantly accelerated and
enhanced the sputum smear conversion rate. Clinical and
radiological improvements resulting from the combination of
Dzherelo and ATT occurred earlier and at higher rates than
those from ATT alone. It is hoped that when herbal medi-
cines such as Dzherelo are validated through rigorous scien-
tiﬁc and clinical research, their integration into modern
medical practice will be more readily accepted and treatment
options for TB will be expanded as a result.
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